Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

Myelodysplastic syndromes (MDS) are inherently resistant to chemotherapy leaving allogeneic stem cell transplantation (HCT) as the only curative treatment option. To date it remains unclear how to ...